AzTrials
AzTrials

ObesitySCHIZOBARNCT06043206

Bariatric Surgery in Patients With Schizophrenia

An observational study of Obesity and Schizophrenia, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

It is known that schizophrenia is associated with obesity in a significant number of patients and it implies a poor prognostic factor, with weight loss being important in this population. However, data about the prognosis of weight loss surgery in subjects with schizophrenia is scant. Read more about this study

Who is it for?
Any age
Conditions the study is for
Obesity, Schizophrenia
What is being tested?
Bariatric Surgery
Type of treatment
Surgery or procedure
How many people
100 participants
Where
1 siteSpain
Study dates
1 Oct 2022to 30 Jun 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: subjects undergoing bariatric surgery

Who may be able to join

  • Patients with severe obesity undergoing bariatric surgery and with follow-up in Spanish territory.
  • Patient with schizophrenia or schizoaffective disorder.
  • Exclusion) Subjects who do not meet any of the two inclusion criteria
  • Controls: in a 4:1 ratio with cases
  • Patients with severe obesity undergoing bariatric surgery and with follow-up in Spanish territory.
  • Absence of psychiatric pathology
  • Paired with the cases by age, sex, BMI before surgery and type of surgery.
  • Exclusion) Subjects who do not meet any of the two inclusion criteria

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Hospital of Santa Creu i Sant Pau

    Barcelona, 08025

Other trials in Spain

About this study

It is known that schizophrenia is associated with obesity in a significant number of patients and it implies a poor prognostic factor, with weight loss being important in this population. However, data about the prognosis of weight loss surgery in subjects with schizophrenia is scant.

Hypothesis: Bariatric surgery in subjects with schizophrenia leads to an improvement in weight and cardiometabolic comorbidities similar to that of subjects without schizophrenia Main goal: To study the evolution after bariatric surgery in patients with obesity and schizophrenia Design: Multicenter retrospective case control study. Disease under study: Schizophrenia and Obesity Methodology: Retrospective observational study Study population and total number of subjects Cases: Patients with schizophrenia and obesity undergoing bariatric surgery. (number: all cases collected within the GOSEEN group).

Read more

Controls: Patients without psychiatric pathology matched by age, sex, body mass index and type of surgery and in a 4:1 ratio to cases.

Calendar. Expected duration of the study. 12 months ethical considerations Informed consent will be obtained from patients who are currently being followed up at the reference centers.

Read the detailed description

THEORETICAL FRAMEWORK. PROBLEM STATEMENT:

Background Obesity affects approximately 45-55% of patients with schizophrenia (1). Weight gain in these patients may be due to different factors such as the use of antipsychotic drugs with an unfavorable metabolic profile, the coexistence of sleep disorders or negative cognitive symptoms that often translate into a more sedentary lifestyle and alterations in eating behavior, among others (2). The coexistence of obesity and its comorbidities in this group of patients significantly worsens both their physical and mental health (3). In fact, cardiovascular disease is one of the main causes of mortality in patients with schizophrenia (4).

Lifestyle interventions, while they may be effective in people with schizophrenia (5), often fall short of achieving weight goals. At present, obesity surgery represents the most effective treatment in terms of weight loss and resolution of comorbidities, being indicated in cases of patients with a body mass index (BMI) > 35 kg/m2 with comorbidities or BMI > 40 Kg/m2 with/without comorbidities. However, the access of patients with schizophrenia to bariatric surgery techniques is usually limited by different factors such as fear of a possible worsening of the underlying disease, or a lower weight loss in this population, among others. In addition, clinical practice guidelines recommend that all patients with psychiatric pathologies be evaluated in a regulated manner prior to surgery (6), although the content of this evaluation and the criteria for declining or accepting surgery are not clear. Although the course of schizophrenia is variable and its symptoms may be stable without being a clear contraindication for bariatric surgery, in actual practice, a considerable number of professionals contraindicate bariatric surgery in the presence of a psychotic disorder (7).

For these reasons, data on the efficacy of bariatric surgery in patients with schizophrenia are scarce and limited to very small case series with short-term follow-up (2,8,9). Our objective is therefore to carry out a multicenter retrospective study that allows us to study the long-term evolution after bariatric surgery in a large series of patients, focusing not only on weight evolution but also on the long-term evolution of psychiatric pathology.

Justification It is necessary to have information about the prognosis of subjects with severe obesity and schizophrenia who undergo bariatric surgery. This knowledge will make it possible to establish clear guidelines for action in these cases.

Research questions What is the long-term outcome after bariatric surgery in subjects with schizophrenia? Hypothesis Bariatric surgery in subjects with schizophrenia leads to an improvement in weight and cardiometabolic comorbidities similar to that of subjects without schizophrenia

GOALS:

Main goal:

To study the short (first year after bariatric surgery) and long-term (up to 5 years of follow-up after bariatric surgery) evolution in terms of weight loss of patients with obesity and schizophrenia who underwent bariatric surgery in Spain and compare it with the evolution of patients without psychiatric disorder.

Secondary objectives:

  • Determine the casuistry of patients, with special interest in the characteristics of the underlying psychiatric pathology (years of evolution, clinical stability criteria, pharmacological treatment...).
  • To Analyze the evolution of obesity comorbidities.
  • To Analyze the evolution of psychiatric pathology after bariatric surgery: (decompensation, drug treatment...)
  • To analyze the frequency of early (<30 days post-surgery) or late (>30 days post-surgery) post-surgical complications.

METHODS:

Study design Retrospective case-control study.

Expected sample size All cases detected in Spanish territory The minimum number of cases expected will be 10 patients based on the low casuistry of the problem. The number of patients in the control group will be x4 that in the study group.

Methodology. Information sources The study population will be identified in each center in the usual specialty consultations or by searching the databases of each center. Review of medical records in search of the specified variables (retrospective observational study).

Data Management and Analysis The coordinating researcher (Dra Inka Miñambres Donaire) will be responsible for the creation of the database and its exploitation. The database will be created in Excell format and the SPSS program will be used for statistical analysis. The statistics will be mainly descriptive. For cases in which it is decided to compare groups, normality tests will be used to establish the behavior of the variables and parametric/non-parametric tests will be used as appropriate.

Data collection The researcher will guarantee the accuracy and integrity of the data, as well as all the reports that are required. The data included in the Data Collection Notebook (CRD), which are derived from source documents, will be consistent with those documents or otherwise the discrepancies will be justified.

The researcher will keep the study documents until at least 5 years after completion.

At the request of the monitor, auditor, ethics committee or health authority, the researcher will have available all the files related to the study, allowing direct access to the data or source documents for monitoring, auditing, review by the ethics committee, as well as the inspection of the trial by the competent authorities.

Limitations of the design, the source of information and the methods of analysis

The main limitation of the study is its retrospective nature. However, the study design is adequate given the low frequency of the pathology.

Data confidentiality Regarding the confidentiality of the study data, the provisions of Organic Law 3/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights and the General Regulation (EU) on Data Protection will be followed. 2016/679.

Interference with physician's prescribing habits As it is a retrospective study, there will be no interference with the prescribing habits of the doctor.

Being tested
Bariatric Surgery
Keywords
Bariatric Surgery, Hospital care, Observational study, weight loss, evolution
Medical subject headings
Obesity, Schizophrenia, Weight Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bariatric SurgeryProcedure or surgery

    Bariatric Surgery

Study groups in NCT06043206
Study groupRoleWhat they receive
Cases Obesity and schizophreniaPatients with schizophrenia and obesity undergoing bariatric surgery
Receives: Procedure: Bariatric Surgery
ControlsPatients without psychiatric pathology matched by age, sex, BMI and type of surgery and in a 4:1 ratio to cases.
Receives: Procedure: Bariatric Surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Weight loss

    short (first year after bariatric surgery) and long-term (up to 5 years of follow-up after bariatric surgery) evolution in terms of weight loss of patients with obesity and schizophrenia who underwent bariatric surgery

    Measured: 12 months and 5 years after the surgery

Secondary outcomes (4)
  1. Clincial Caracteristics description

    casuistry of patients, with special interest in the characteristics of the underlying psychiatric pathology (years of evolution, clinical stability criteria, pharmacological treatment...)

    Measured: inclusion, day 1

  2. Comorbidity progression

    Analyze the evolution of obesity comorbidities: presence of type 2 diabetes, hypertension, OSAS and dyslipidemia. Remission of co morbidities was defined as cessation of medication for hypertension or hyperlipidemia with normal blood pressure and lipid levels, cessation for continuous positive pressure ventilation for sleep apnea, and normalization of HbA1C (<6.5) with no medications for diabetes.

    Measured: 12 months and 5 years after the surgery

  3. Psychiatric pathology progression

    Analyze the evolution of psychiatric treatment: Psychiatric medication burden will be calculated by generating a continuous variable using a previous validated formula (Central Nervous System Medication Burden and Serious Falls in Older Nursing Home Residents Joseph T. Hanlon, J Am Geriatr Soc. 2017 June ; 65(6): 1183-1189. doi:10.1111/jgs.14759).

    Measured: 30 days post surgery and 5 years after the surgery

  4. post-surgical complications

    To analyze the frequency of early or late post-surgical complications

    Measured: up to 30 days post-surgery) or late post-surgical complications (through study completion, up to five years post-surgery)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2023
  2. Study start1 Oct 2022
  3. Primary completion30 Jun 2023
  4. Study completion30 Jun 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06043206
Sponsor's protocol ID
IIBSP-BAR-2022-30
Acronym
SCHIZOBAR
Status last verified
Sep 2023
First submitted
3 Sep 2023
Last updated
21 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: individual participant data can not be available due to the data protection law restrictions, however, anonymized data could be shared on demand

Questions about this trial

What is this clinical trial studying?

An observational study of Obesity and Schizophrenia, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Weight loss (time frame: 12 months and 5 years after the surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in